<DOC>
	<DOCNO>NCT01242527</DOCNO>
	<brief_summary>The primary objective study determine efficacy Epanova ( omefas ) compare placebo lower serum triglyceride subject severe hypertriglyceridemia .</brief_summary>
	<brief_title>Epanova® Lowering Very High Triglycerides</brief_title>
	<detailed_description />
	<mesh_term>Hypertriglyceridemia</mesh_term>
	<criteria>Men woman , &gt; =18 year age . Very high serum TG value range &gt; =500 mg/dL &lt; 2000 mg/dL ( &gt; =5.65 mmol/L &lt; 22.60 mmol/L ) Allergy intolerance omega3 fatty acid , omega3acid ethyl ester , fish . Known lipoprotein lipase impairment deficiency apolipoprotein CII deficiency familial dysbetalipoproteinemia . Unable discontinue use omega3 drugs/supplements . Unable discontinue use bile acid sequestrants , fibrates niacin ( niacincontaining vitamin &lt; 200 mg ) , supplement use alter lipid metabolism . Women pregnant , lactating , plan become pregnant . Women childbearing potential use acceptable contraceptive method . Use tamoxifen , estrogens progestin stable &gt; 4 week prior Visit 1 . Use oral injected corticosteroid anabolic steroid . History pancreatitis . History symptomatic gallstone disease , unless treat cholecystectomy . Uncontrolled diabetes . Uncontrolled hypothyroidism thyroid stimulate hormone ( TSH ) . History cancer ( basal cell carcinoma ) past 2 year . Cardiovascular event ( i.e. , myocardial infarction , acute coronary syndrome , new onset angina , stroke , transient ischemic attack , unstable congestive heart failure require change treatment ) revascularization procedure within six month prior Visit 1 . Use anticoagulant ( e.g . warfarin [ Coumadin® ] , coumarin , heparin , enoxaparin , clopidogrel ) . Presence aortic aneurysm resection aortic aneurysm within six month prior Visit 1 . Recent history ( within six month prior Visit 1 ) current significant nephrotic syndrome , pulmonary , hepatic , biliary , gastrointestinal immunologic disease . Poorly control hypertension . Any following laboratory criterion : serum alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) , glucose , glomerular filtration rate ( GFR ) , platelet count , hemoglobin outside study range . Recent history ( past 12 month ) drug abuse alcohol abuse . Exposure investigational product , within 4 week prior Visit 1 . Presence condition Investigator believe would interfere subject 's ability provide inform consent , comply study instruction , might confound interpretation study result put subject undue risk</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>dyslipidemia</keyword>
	<keyword>hyperlipidemia</keyword>
	<keyword>omega-3 carboxylic acid</keyword>
</DOC>